FAB Pharma, A Biopharma Company Developing Drugs To Treat Severe Bacterial Infections

Medical News Today reports that, FAB Pharma has acquired assets in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) from Mutabilis S.A. Severe infections caused by MRSA is a growing issue, especially in the hospital where it is one of the main causes of nosocomial infections. By definition, MRSA is resistant to a broad group of antibiotics. FAB Pharma's approach consists in developing a new class of low-molecular-weight antibacterial molecules which target a specific, essential enzyme in MRSA called Fatty Acid Biosynthesis I (FAB I).

There is a growing medical need for anti-MRSA drugs. Nosocomial infections constitute a major health problem, with 4 million cases reported each year in Europe and 2 million a year in the USA.

Will the anti-MSRA drug that FAB Pharma is developing work to help this millions of infected persons? Are there other companies working on a similar drug?


FAB Pharma, A Biopharma Company Developing Drugs To Treat Severe Bacterial Infections

Share this article with your social network, just click below to share now!

Share |